News Report | March 16, 2023
DEA Proposes Permanent Telemedicine Flexibilities For Buprenorphine Prescribing
On February 24, 2023, the Drug Enforcement Administration (DEA) proposed permanent rules for prescribing controlled medications via telemedicine, including buprenorphine for opioid addiction treatment. Public comments will be accepted through March 23, 2023. Under the proposed rules, remote medical professionals can prescribe a 30-day supply of Schedule III-V non-narcotic controlled medications and a 30-day supply of buprenorphine for the treatment of opioid use disorder for those consumers not yet seen in person. To continue prescribing, the clinical professional will need to meet with the consumer for an in-person medical examination.
The proposed rules extend many . . .